MAPK1 and prostate cancer: Activated ERK has been elicited Form 91% out of 101 head and neck cancer samples, 84% of 60 prostate cancer samples, 72% out of 90 breast cancer samples and 67% out of 74 gastric cancer samples respectively [60, 61].